实体器官移植中耳念珠菌筛查的伦理优先事项
Ethical Priorities for Candida auris Screening in Solid Organ Transplantation
耳念珠菌是一种新发、多重耐药的真菌，在实体器官移植中日益受关注，定植可能影响移植候选资格和移植后结局。但目前美国没有国家或专业指南规定筛查对象、方法和时机，对筛查结果如何影响诊疗也无共识。本文分析耳念珠菌定植在移植资格决策中的伦理意义，梳理支持与反对在移植前后对所有受者普遍筛查的理由，并提出“基于风险的筛查”作为折中方案。作者强调移植前筛查的根本目的是通过准备和个体化风险评估来减少伤害，而非体现机构的风险容忍度。
为什么推荐给您：针对新兴耐药真菌筛查缺指南提出的伦理框架与风险分层建议，属新技术带来的新伦理问题。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Candida auris is an emerging, multidrug-resistant fungal pathogen of growing concern in solid organ transplantation, where colonization may have implications for pretransplant candidacy and post-transplant outcomes. Although C. auris screening is increasingly common in presurgical and critical care settings, no national or professional guidelines in the United States specify who, how, or when to screen, nor is there consensus on how screening results should impact patient care. Here, we examine the ethical significance of C. auris colonization in transplant candidacy decisions and outline the arguments for and against universal C. auris screening of solid organ recipients in the peritransplant period. We propose risk-based screening as a middle-ground approach for hospitals and physicians seeking to develop value-informed, evidence-based guidelines at a time when data are still emerging and evolving. Ultimately, the fundamental goal of pretransplant screening is harm reduction through preparedness and individualized risk assessment, not a proxy for institutional risk tolerance or an artifact of how a screening policy is applied.